Search
Highlights from the SWG
During 2023, the SWG:
Held a joint scientific meeting with the SWG on Myelodysplastic Syndromes and the SWG on Acute Myeloid Leukemia
Commenced work on guidelines for young MPN patients
Delivered a presentation for the American Society of Hematology (ASH) on the database…
Policy & advocacy
At the core of EHA’s advocacy efforts are four priority themes. For each of these themes, the main messages and recommendations directed at EU institutions and other stakeholders have been written down in a Position Paper.
Read moreSelected EMA news
Most of EHA’s regulatory activities focus on collaboration with the European Medicines Agency (EMA).
Read more3rd Highlights of Past EHA (HOPE) in 2020 focused on Latin America a success!
November 13, 2020
Meeting Chairs:
Prof J Gribben (European Hematology Association)
Prof G Stemmelin (Argentinian Society of Hematology)
On November 13, EHA and the Argentinian Society of Hematology (SAH) kicked-off the second HOPE Latin America meeting in a virtual format.
EHA-Balkan Hematology Day 2023
EHA is joining forces with the national societies from the Balkan countries and co-organizing with them the 4th edition of the EHA-Balkan Hematology Day.
Read moreCompliance and reports
EHA is a non-governmental and not-for-profit membership organization that is guided by its mission to promote excellence in patient care, research, and education in hematology.
Read moreEuropean Working Group for Adult Acute Lymphoblastic Leukemia (EWALL)
The specialized working group on adult acute lymphoblastic leukemia (EWALL) consists mainly of the members of the EWALL group, which is the European Working Group for Adult ALL, and which includes the leaders of the national ALL study groups in Europe.…
Read moreEHA-SWG Scientific Meeting on Recent Advances in the Pathogenesis and Treatment of Secondary Acute Myeloid Leukemias
Dates: April 25-26, 2025
Location: to be announced
Chairs: K Döhner, P Vyas, and MT Voso
Collaborating SWG: EHA Specialized Working Group on Acute Myeloid Leukemia
Registration will be open soon
Program The EHA-SWG scientific meeting on Recent Advances in the Pathogenesis and Treatment of Secondary Acute Myeloid…
Survey Monitoring H2020 – your input is needed!
We need your input to improve Horizon 2020 and the next Research and Innovation Framework Programme of the European Union.
Read moreThe root of evil: pre-leukemic clones that survive chemotherapy are linked to a higher risk of leukemia recurrence
Acute myeloid leukemia (AML) is an aggressive form of blood cancer. Treatment with intensive chemotherapy often leads to a period of freedom from overt disease called a remission. However, recurrence of the disease is common.
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- »